This review discusses the development and clinical progress of oral selective estrogen receptor degraders (SERDs) as a novel endocrine therapy for estrogen receptor-positive (ER+) breast cancer. ER+ breast cancer accounts for a significant proportion of breast cancer cases, and endocrine therapies are often the first-line treatment. However, the development of drug resistance poses a significant challenge. Second-generation SERDs, which are taken orally, offer a more convenient and effective treatment option for patients who develop resistance to endocrine therapies. Elacestrant, the first oral SERD to receive FDA approval, has shown promising results in treating ER+ HER2-negative metastatic breast cancer. Other oral SERDs, such as camizestrant, giredestrant, amenestrant, imlunestrant, rintodestrant, AZD9496, borestrant, D-0502, and ZN-c5, are also under investigation in clinical trials. These drugs demonstrate meaningful efficacy and manageable safety in early-stage clinical trials. The review highlights the potential of oral SERDs to improve treatment outcomes for ER+ breast cancer patients, particularly those with *ESR1* mutations, and discusses the ongoing clinical trials and future perspectives.This review discusses the development and clinical progress of oral selective estrogen receptor degraders (SERDs) as a novel endocrine therapy for estrogen receptor-positive (ER+) breast cancer. ER+ breast cancer accounts for a significant proportion of breast cancer cases, and endocrine therapies are often the first-line treatment. However, the development of drug resistance poses a significant challenge. Second-generation SERDs, which are taken orally, offer a more convenient and effective treatment option for patients who develop resistance to endocrine therapies. Elacestrant, the first oral SERD to receive FDA approval, has shown promising results in treating ER+ HER2-negative metastatic breast cancer. Other oral SERDs, such as camizestrant, giredestrant, amenestrant, imlunestrant, rintodestrant, AZD9496, borestrant, D-0502, and ZN-c5, are also under investigation in clinical trials. These drugs demonstrate meaningful efficacy and manageable safety in early-stage clinical trials. The review highlights the potential of oral SERDs to improve treatment outcomes for ER+ breast cancer patients, particularly those with *ESR1* mutations, and discusses the ongoing clinical trials and future perspectives.